ThomasSaphnerMD

Oncology • Two Rivers, WI

Breast Cancer, Hematologic Oncology

Medical Oncologist at Aurora Health

Join to view full profile

Dr. Saphner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Saphner's full profile

Already have an account?

Office
5300 Memorial Drive
Two Rivers, WI 54241
Phone+1 920-793-6100
Is this information wrong?

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1988 - 1991
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1987 - 1988
University of Kentucky College of MedicineResidency, Internal Medicine, 1985 - 1987
University of Wisconsin School of Medicine & Public HealthClass of 1985

Certifications & Licensure

WI State Medical License 1987 - 2025
MI State Medical License 1991 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACP) American College of Physicians, 1998

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Understanding and Predicting Breast Cancer Events After Treatment Start of enrollment: 2017 Jul 21
Active, not recruiting
Not Applicable
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil Start of enrollment: 2017 May 30
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Antonio C Wolff, Mark R Somerfield, Mitchell Dowsett, M Elizabeth H Hammond, Daniel F Hayes, Lisa M McShane, Thomas J Saphner, Patricia A Spears, Kimberly H Allison> ;Archives of Pathology & Laboratory Medicine. 2023 Sep 1
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Rand...
Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas, Kathryn J Ruddy, Thomas James Saphner, Heshan Liu, Elizabeth Harlos, Adedayo A Onitilo, Karthik Giridha...> ;The Oncologist. 2023 Aug 3
50 citations
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
Antonio C Wolff, Mark R Somerfield, Mitchell Dowsett, M Elizabeth H Hammond, Daniel F Hayes, Lisa M McShane, Thomas J Saphner, Patricia A Spears, Kimberly H Allison> ;Journal of Clinical Oncology. 2023 Aug 1
A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention.
Daniel L Hall, Beverly J Levine, Elizabeth Jeter, Allison Chandler, Janet A Tooze, Jenna Duffecy, David Victorson, William Gradishar, Joseph Leach, Thomas Saphner, Mar...> ;Journal of Behavioral Medicine. 2022 Oct 1
26 citations
Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results from the FoRtitude Randomized Trial.
Lynne I. Wagner, Janet A. Tooze, Daniel L. Hall, Beverly J. Levine, Jennifer L. Beaumont, Jenna Duffecy, David Victorson, William J. Gradishar, Joseph W. Leach, Thomas...> ;Journal of the National Cancer Institute. 2021 May 31
12 citations
Clinical trial participation assessed by age, sex, race, ethnicity, and socioeconomic status.
Thomas J Saphner, Andy Marek, Jennifer K. Homa, Lisa Robinson, Neha Glandt> ;Contemporary Clinical Trials. 2021 Feb 21
60 citations
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Kathy S. Albain, Robert Gray, Della F. Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, S...> ;Journal of the National Cancer Institute. 2021 Apr 6
95 citations
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analys...
Joseph A. Sparano, Robert Gray, DF Makower, Kathy S. Albain, Thomas James Saphner, Sunil Badve, Lynne I. Wagner, Virginia G. Kaklamani, Maccon M. Keane, Henry L. Gomez...> ;JAMA Oncology. 2020 Mar 1
286 citations
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A. Sparano, Robert Gray, Peter M. Ravdin, Della F. Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Ma...> ;The New England Journal of Medicine. 2019 Jun 3
1253 citations
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert Gray, Della F. Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, J...> ;The New England Journal of Medicine. 2018 Jun 3
11 citations
Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study
Julie E. Chang, Songwong Seo, KyungMann Kim, Jae Werndli, Wayne A. Bottner, Gilberto A. Rodrigues, Federico A. Sanchez, Thomas J. Saphner, Walter L. Longo, Brad S. Kahl> ;Clinical Lymphoma, Myeloma & Leukemia. 2010 Oct 1
56 citations
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.
Kathy D. Miller, Thomas J. Saphner, David M. Waterhouse, Tai-Tsang Chen, Anita Rush-Taylor, Joseph A. Sparano, Antonio C. Wolff, Melody A. Cobleigh, Susan Galbraith, G...> ;Clinical Cancer Research. 2004 Mar 15
615 citations
Annual hazard rates of recurrence for breast cancer after primary therapy.
Thomas James Saphner, Douglass C. Tormey, Robert Gray> ;Journal of Clinical Oncology. 1996 Oct 1
14 citations
Phase II study of goserelin for patients with postmenopausal metastatic breast cancer.
Thomas James Saphner, A B Troxel, Douglass C. Tormey, Donna Neuberg, Nicholas J. Robert, Kishan J. Pandya, John H. Edmonson, Richard J. Rosenbluth, Martin D. Abeloff> ;Journal of Clinical Oncology. 1993 Aug 1
4 citations
Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: Feasibility study
Thomas Saphner, Douglass C. Tormey, Patrick Carey> ;Medical and Pediatric Oncology. 1992 Jan 1
6 citations
Continuous infusion 5‐fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study
Thomas James Saphner, Douglass C. Tormey, Mark R. Albertini> ;Cancer. 1991 Dec 1
310 citations
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.
Thomas James Saphner, Douglass C. Tormey, Robert Gray> ;Journal of Clinical Oncology. 1991 Feb 1
52 citations
Neurologic complications of cervical cancer. A review of 2261 cases.
Thomas James Saphner, Holly H. Gallion, John R. van Nagell, Richard J. Kryscio, Roy A. Patchell> ;Cancer. 1989 Sep 1
Join now to see all

Journal Articles

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Press Mentions

How Some Breast Cancer Patients Are Safely Skipping ChemotherapyJanuary 17th, 2023
Bringing Clinical Trials to the Community Health Clinic: Advocate Aurora Health Receives $10.2mAugust 21st, 2019
New Funding for Cancer Trials • Public Charge Rule Could Cost Hospitals • Hospital Star Ratings Will ChangeAugust 21st, 2019
Join now to see all